Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1481 to 1490 of 1856 total matches.

Capmatinib (Tabrecta) for NSCLC (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
cannot tolerate the 200-mg dose. A 30-day supply of Tabrecta costs about $23,120.3 CONCLUSION — In one ...
The FDA has granted regular approval to the oral kinase inhibitor capmatinib (Tabrecta – Novartis) for treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. MET exon 14 skipping mutations occur in 3-4% of NSCLC cases. The drug received accelerated approval for the same indication in 2020 based on initial overall response rates and duration of response.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e65-6   doi:10.58347/tml.2023.1674d |  Show IntroductionHide Introduction

In Brief: A New Indication for Tenecteplase (TNKase)

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
, with higher scores indicating greater disability) 90–120 days after treatment. At the time of data cutoff ...
The tissue plasminogen activator (tPA) tenecteplase (TNKase – Genentech) has been approved by the FDA for treatment of acute ischemic stroke in adults. It is the second tPA to be approved in the US for this indication; alteplase (Activase) was approved in 1996. Tenecteplase was approved in 2000 to reduce the risk of death associated with acute ST-elevation myocardial infarction (STEMI).
Med Lett Drugs Ther. 2025 Apr 28;67(1727):71-2   doi:10.58347/tml.2025.1727d |  Show IntroductionHide Introduction

Perinatal Toxicity of Cocaine

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 1988  (Issue 767)
were still present in 10 infants at eight to 19 days, but only one by three to 12 months (TM Doberczak ...
As cocaine continues to be widely available in the USA (Medical Letter, 28:69, 1986), new problems associated with its use continue to emerge. Some recent reports indicate that use of the drug during pregnancy can damage the fetus, lead to abortion or premature labor, and cause toxic effects in the newborn infant.
Med Lett Drugs Ther. 1988 Jun 3;30(767):59-60 |  Show IntroductionHide Introduction

NovolinPen for Insulin Injection

   
The Medical Letter on Drugs and Therapeutics • Dec 30, 1988  (Issue 782)
a day; if regular and NPH insulin are required at different times, only the cartridge needs ...
The NovolinPen (Squibb - Novo) is a device that uses prefilled cartridges to inject semisynthetic human insulin (Medical Letter, 25:63, 1983). Three formulations are available: regular insulin (Novolin R PenFill), NPH insulin isophane (Novolin N PenFill) and a mixture of 70% NPH and 30% regular (Novolin 70/30 PenFill). The NovolinPen is advertised as more accurate, more convenient and less expensive than conventional syringes and needles. The same device is marketed in Canada as the Novolin-Pen II (Connaught Novo). (An earlier device is also available as the Novolin-Pen in Canada and the...
Med Lett Drugs Ther. 1988 Dec 30;30(782):117-8 |  Show IntroductionHide Introduction

Dezocine

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 1990  (Issue 829)
days. ADVERSE EFFECTS — Nausea, vomiting, and sedation occur with dezocine about as often ...
Dezocine (Dalgan - Astra), a new synthetic opioid agonist/antagonist structurally related to pentazocine (Talwin), was recently approved for parenteral use as an analgesic by the US Food and Drug Administration.
Med Lett Drugs Ther. 1990 Oct 19;32(829):95-6 |  Show IntroductionHide Introduction

Pegaspargase for Acute Lymphoblastic Leukemia

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 1995  (Issue 944)
) or subcutaneously (SC) every 14 days. Some patients may require weekly treatment. Asparaginase from E. coli ...
Pegaspargase (peg as par jase; PEG-L-asparaginase; Oncaspar - Rh ne-Poulenc Rorer), a polyethylene glycol (PEG) conjugate of L-asparaginase, has been approved by the US Food and Drug Administration for treatment of acute lymphoblastic leukemia (ALL), the most common malignancy of childhood. The new drug is recommended only for patients who have had allergic reactions to asparaginase. Asparaginase is available commercially as Elspar, which is derived from Escherichia coli. A formulation derived from Erwinia chrysanthemi is available on an investigational basis (Ogden Bioservices,...
Med Lett Drugs Ther. 1995 Mar 17;37(944):23-4 |  Show IntroductionHide Introduction

Abciximab to Prevent Vessel Closure After Angioplasty

   
The Medical Letter on Drugs and Therapeutics • Jun 09, 1995  (Issue 950)
received intravenous heparin and oral aspirin. The primary endpoint was the occurrence within 30 days after ...
Abciximab (ab sik si mab; ReoPro - Centocor), the Fab (fragment antigen binding) fragment of the chimeric human-murine monoclonal antibody 7E3 (c7E3 Fab), has been approved by the US Food and Drug Administration as an adjunct to percutaneous transluminal coronary angioplasty or atherectomy (PTCA) to prevent abrupt closure of the treated coronary vessel.
Med Lett Drugs Ther. 1995 Jun 9;37(950):52-3 |  Show IntroductionHide Introduction

Epoprostenol for Primary Pulmonary Hypertension

   
The Medical Letter on Drugs and Therapeutics • Feb 16, 1996  (Issue 968)
administration, including two pumps, are also provided by Quantum, at the cost of $108.68 per day. The total ...
Epoprostenol sodium (Flolan - Glaxo Wellcome), also known as prostacyclin, has been approved by the US Food and Drug Administration for continuous intravenous treatment of primary pulmonary hypertension.
Med Lett Drugs Ther. 1996 Feb 16;38(968):14-5 |  Show IntroductionHide Introduction

Ibutilide

   
The Medical Letter on Drugs and Therapeutics • Apr 12, 1996  (Issue 972)
tachycardia) were excluded. In 200 patients with recent onset (three hours to 90 days) of atrial fibrillation ...
Ibutilide fumarate (Corvert - Pharmacia & Upjohn), a new antiarrhythmic drug for intravenous use, has been approved by the US Food and Drug Administration for acute termination of atrial fibrillation or flutter of recent onset.
Med Lett Drugs Ther. 1996 Apr 12;38(972):38 |  Show IntroductionHide Introduction

Glatiramer Acetate for Relapsing Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Jul 04, 1997  (Issue 1004)
− Betaseron (Berlex) 8 million units every other day SC 10,980 * Cost to the pharmacist for one year’s ...
Glatiramer acetate (Copaxone - Teva Marion Partners), formerly known as copolymer-l, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis (MS). Interferon β-1b (Betaseron) and interferon β-1a (Avonex - Medical Letter, 38:63, 1996) were previously approved for this indication.
Med Lett Drugs Ther. 1997 Jul 4;39(1004):61-2 |  Show IntroductionHide Introduction